Latest Market News

Wellnex Life reports encouraging early results from its turnaround strategy, posting a modest EBITDA profit and robust sales growth for its Pain Away brand.

Tinybeans Group has completed a partially underwritten entitlement offer, raising $1.7 million to support growth and working capital, with plans to place the remaining shortfall soon.

Paterson Resources has wrapped up the first phase of its drilling campaign at the Grace Gold-Copper Project, setting the stage for a resource upgrade and scoping study in 2026.

Intelligent Monitoring Group Limited has raised $20 million through a strategic equity placement to support its recent acquisitions and stabilize its financial position. The capital raise aims to broaden the investor base and enhance market liquidity ahead of the new year.

E79 Gold Mines has initiated a high-resolution gravity survey at its newly acquired Cue Gold Project in Western Australia, aiming to reveal hidden gold structures and define drill targets for early 2026.

International Graphite Limited has signed a non-binding letter of intent with Alkeemia S.p.A to access graphite purification tolling services at a new Italian plant starting early 2026, aiming to boost its high-purity graphite supply while minimizing capital costs.

Gibb River Diamonds has begun trucking and processing operations at its Neta Gold Mine, securing 130,000 tonnes of ore for milling at two contracted facilities in Western Australia.

CONNEQT Health’s Pulse arterial health monitor sales have outpaced expectations with over 200% growth in the December quarter, driven by efficient marketing and early subscription uptake.

Gold Hydrogen Limited’s latest drilling at Ramsay 4 confirms significant natural hydrogen and helium formations, setting the stage for critical flow testing in early 2026 to assess commercial viability.

Aureka Limited has raised $3.6 million through a share placement to fund a second diamond drill rig and accelerate exploration at its Victorian gold projects, reflecting strong investor confidence following recent high-grade discoveries.

Recce Pharmaceuticals has won a significant Australian Government R&D tax incentive, unlocking up to A$85 million for its synthetic anti-infective programs worldwide, including a pivotal Phase 3 clinical trial.

HITIQ Limited has successfully completed the initial tranche of a $900,000 placement, issuing over 40 million shares with attached options, while director participation awaits shareholder approval.